NFC
JAZZ icon

Northeast Financial Consultants’s Jazz Pharmaceuticals JAZZ Stock Holding History

Northeast Financial Consultants’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,270
Closed -$479K – 312
2023
Q1 		$479K Hold
3,270
– – 0.03% 196
2022
Q4 		$521K Buy
+3,270
New +$479K 0.04% 182

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Northeast Financial Consultants's JAZZ Position: Q2 2023 in Review

Northeast Financial Consultants sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 3,270 shares — an estimated $479K sold.

Northeast Financial Consultants first reported a position in JAZZ in Q4 2022 and held it in 2 quarters. The position peaked at $521K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

  • Northeast Financial Consultants reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Northeast Financial Consultants sold 3,270 Jazz Pharmaceuticals shares in Q2 2023, an estimated $479K.
  • Northeast Financial Consultants first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Northeast Financial Consultants's Jazz Pharmaceuticals position peaked at $521K in Q4 2022.
  • 471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Northeast Financial Consultants's 13F filing for Q2 2023, filed 8 Aug 2023.